|  | Pingvin (N=27) | Søløve (N=26) | Overall (N=53) |
| --- | --- | --- | --- |
| **SLICC-Eular/ACR-2019** |  |  |  |
| N | 27 | 25 | 52 |
| Mean (SD) | 28.5 (8.55) | 22.6 (8.26) | 25.7 (8.83) |
| Median [Q1, Q3] | 30.0 [20.5, 35.0] | 20.0 [17.0, 27.0] | 23.0 [18.0, 34.0] |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **Anti-DsDNA (SLICC-Eular/ACR-2019)** | 20 (74 %) | 10 (38 %) | 30 (57 %) |
| No | 7 (26 %) | 15 (58 %) | 22 (42 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **Anti-Smith (SLICC-Eular/ACR-2019)** | 3 (11 %) | 3 (12 %) | 6 (11 %) |
| No | 24 (89 %) | 22 (85 %) | 46 (87 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **Fever (SLICC-Eular/ACR-2019)** | 20 (74 %) | 19 (73 %) | 39 (74 %) |
| No | 7 (26 %) | 6 (23 %) | 13 (25 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **Acute Cutaneous Lupus (SLICC-Eular/ACR-2019)** | 6 (22 %) | 7 (27 %) | 13 (25 %) |
| No | 21 (78 %) | 18 (69 %) | 39 (74 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **Subacute Cutaneous or Discoid Lupus (SLICC-Eular/ACR-2019)** | 16 (59 %) | 14 (54 %) | 30 (57 %) |
| No | 11 (41 %) | 11 (42 %) | 22 (42 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **Oral Ulcers (SLICC-Eular/ACR-2019)** | 5 (19 %) | 7 (27 %) | 12 (23 %) |
| No | 22 (81 %) | 18 (69 %) | 40 (75 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **Non-Scarring Alopecia (SLICC-Eular/ACR-2019)** | 7 (26 %) | 7 (27 %) | 14 (26 %) |
| No | 20 (74 %) | 18 (69 %) | 38 (72 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **No Mucocutaneous Symptoms (SLICC-Eular/ACR-2019)** | 3 (11 %) | 2 (8 %) | 5 (9 %) |
| No | 24 (89 %) | 23 (88 %) | 47 (89 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **Synovitis (SLICC-Eular/ACR-2019)** | 16 (59 %) | 13 (50 %) | 29 (55 %) |
| No | 11 (41 %) | 12 (46 %) | 23 (43 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **Athralgias (SLICC-Eular/ACR-2019)** | 19 (70 %) | 16 (62 %) | 35 (66 %) |
| No | 8 (30 %) | 9 (35 %) | 17 (32 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **No joint pain or swelling (SLICC-Eular/ACR-2019)** | 1 (4 %) | 1 (4 %) | 2 (4 %) |
| No | 26 (96 %) | 24 (92 %) | 50 (94 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **Seizures (SLICC-Eular/ACR-2019)** | 4 (15 %) | 1 (4 %) | 5 (9 %) |
| No | 23 (85 %) | 24 (92 %) | 47 (89 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **Psychosis (SLICC-Eular/ACR-2019)** | 0 (0 %) | 0 (0 %) | 0 (0 %) |
| No | 27 (100 %) | 25 (96 %) | 52 (98 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **Delirium (SLICC-Eular/ACR-2019)** | 4 (15 %) | 0 (0 %) | 4 (8 %) |
| No | 23 (85 %) | 25 (96 %) | 48 (91 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **No neurologic symptoms (SLICC-Eular/ACR-2019)** | 19 (70 %) | 24 (92 %) | 43 (81 %) |
| No | 8 (30 %) | 1 (4 %) | 9 (17 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **Acute Pericarditis (SLICC-Eular/ACR-2019)** | 0 (0 %) | 1 (4 %) | 1 (2 %) |
| No | 27 (100 %) | 24 (92 %) | 51 (96 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **Pleural or Pericardial Effusion (SLICC-Eular/ACR-2019)** | 10 (37 %) | 9 (35 %) | 19 (36 %) |
| No | 17 (63 %) | 16 (62 %) | 33 (62 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **No serositis (SLICC-Eular/ACR-2019)** | 17 (63 %) | 15 (58 %) | 32 (60 %) |
| No | 10 (37 %) | 10 (38 %) | 20 (38 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **Autoimmune Hemolytic Anemia (SLICC-Eular/ACR-2019)** | 10 (37 %) | 7 (27 %) | 17 (32 %) |
| No | 17 (63 %) | 18 (69 %) | 35 (66 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **Thrombocytopenia (SLICC-Eular/ACR-2019)** | 1 (4 %) | 1 (4 %) | 2 (4 %) |
| No | 26 (96 %) | 24 (92 %) | 50 (94 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **Leucopenia (SLICC-Eular/ACR-2019)** | 1 (4 %) | 0 (0 %) | 1 (2 %) |
| No | 26 (96 %) | 25 (96 %) | 51 (96 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **No Hematologic Symptoms (SLICC-Eular/ACR-2019)** | 16 (59 %) | 17 (65 %) | 33 (62 %) |
| No | 11 (41 %) | 8 (31 %) | 19 (36 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **Class III or IV Nephritis (SLICC-Eular/ACR-2019)** | 10 (37 %) | 4 (15 %) | 14 (26 %) |
| No | 17 (63 %) | 21 (81 %) | 38 (72 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **Class II or V Nephritis (SLICC-Eular/ACR-2019)** | 2 (7 %) | 1 (4 %) | 3 (6 %) |
| No | 25 (93 %) | 24 (92 %) | 49 (92 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **Proteinuria (SLICC-Eular/ACR-2019)** | 4 (15 %) | 6 (23 %) | 10 (19 %) |
| No | 23 (85 %) | 19 (73 %) | 42 (79 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **No nephrologic symptoms (SLICC-Eular/ACR-2019)** | 21 (78 %) | 18 (69 %) | 39 (74 %) |
| No | 6 (22 %) | 7 (27 %) | 13 (25 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **Anti-Beta2-Glycoprotein (SLICC-Eular/ACR-2019)** | 10 (37 %) | 4 (15 %) | 14 (26 %) |
| No | 17 (63 %) | 21 (81 %) | 38 (72 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **Lupus Anti Coagulant (SLICC-Eular/ACR-2019)** | 5 (19 %) | 2 (8 %) | 7 (13 %) |
| No | 22 (81 %) | 23 (88 %) | 45 (85 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **Anti Cardiolipins (SLICC-Eular/ACR-2019)** | 10 (37 %) | 4 (15 %) | 14 (26 %) |
| No | 17 (63 %) | 21 (81 %) | 38 (72 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **No Anti Phospholipids (SLICC-Eular/ACR-2019)** | 13 (48 %) | 20 (77 %) | 33 (62 %) |
| No | 14 (52 %) | 5 (19 %) | 19 (36 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **Low Complement C3 and C4 (SLICC-Eular/ACR-2019)** | 16 (59 %) | 7 (27 %) | 23 (43 %) |
| No | 11 (41 %) | 18 (69 %) | 29 (55 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **Low Complement C3 or C4 (SLICC-Eular/ACR-2019)** | 2 (7 %) | 6 (23 %) | 8 (15 %) |
| No | 25 (93 %) | 19 (73 %) | 44 (83 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |
| **Normal Complement C3 or C4 (SLICC-Eular/ACR-2019)** | 9 (33 %) | 12 (46 %) | 21 (40 %) |
| No | 18 (67 %) | 13 (50 %) | 31 (58 %) |
| Missing | 0 (0%) | 1 (3.8%) | 1 (1.9%) |